GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (OSTO:VICO BTA) » Definitions » Debt-to-Asset

Vicore Pharma Holding AB (OSTO:VICO BTA) Debt-to-Asset : 0.00 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Vicore Pharma Holding AB Debt-to-Asset?

Vicore Pharma Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Vicore Pharma Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Vicore Pharma Holding AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was kr1,083.33 Mil. Vicore Pharma Holding AB's debt to asset for the quarter that ended in Mar. 2025 was 0.00.


Vicore Pharma Holding AB Debt-to-Asset Historical Data

The historical data trend for Vicore Pharma Holding AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Debt-to-Asset Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vicore Pharma Holding AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vicore Pharma Holding AB's Debt-to-Asset

For the Biotechnology subindustry, Vicore Pharma Holding AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Debt-to-Asset falls into.


;
;

Vicore Pharma Holding AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vicore Pharma Holding AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Vicore Pharma Holding AB's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicore Pharma Holding AB  (OSTO:VICO BTA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Vicore Pharma Holding AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines